Patents Examined by Amy H. Bowman
  • Patent number: 11504402
    Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 22, 2022
    Assignee: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 11499157
    Abstract: The present invention generally relates to specific immune-modulatory RNA species that have a small hairpin structure (shRNA), and that can bind to retinoic acid inducible gene I receptor (RIG-I). In particular, said RNA species comprise a nucleotide insertion to create a kink in the stem region. Also encompassed are compositions comprising such shRNA, for use as antiviral or anticancer medication, or as adjuvants in vaccine.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: November 15, 2022
    Assignees: Nanyang Technological University, Agency for Science, Technology and Research
    Inventors: Dahai Luo, Katja Fink, Hui Yee Yong, Chin Yong Victor Ho
  • Patent number: 11499152
    Abstract: The present disclosure provides compositions and methods that inhibit the activity of microRNAs, for example miR-22.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 15, 2022
    Assignees: Beth Israel Deaconess Medical Center, Aalborg University
    Inventors: Pier Paolo Pandolfi, Riccardo Panella, Sakari Kauppinen, Andreas Petri
  • Patent number: 11492367
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 8, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Patent number: 11492618
    Abstract: The present invention relates to the use of a regulatory nucleic acid sequences that are able to regulate gene expression in eukaryotic cells and which are responsive to the unfolded protein response (UPR). There are disclosed regulatable introns and UPR-inducible promoters, which are able to regulate gene expression. There are also disclosed recombinant expression constructs comprising such regulatory nucleic acid sequences, whereby expression of the encoded expression product can be induced by invoking the unfolded protein response (UPR) in a eukaryotic cell containing the construct, methods of using such constructs and associated vectors, cells and suchlike.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: November 8, 2022
    Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Graham Whyteside
  • Patent number: 11484553
    Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 1, 2022
    Assignee: Baylor College of Medicine
    Inventors: Tanner Monroe, John Leach, James F. Martin
  • Patent number: 11485972
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
  • Patent number: 11479767
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 25, 2022
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps
  • Patent number: 11479769
    Abstract: Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog thereof; and a method for preventing or treating tumors using said composition. The miRNA inhibitory complex preferably includes at least one double-stranded structure and an miRNA-binding sequence. Two strands of the miRNA binding sequence preferably bind individually to two strands on at least one end of the double-stranded structure. According to some of the aspects of the present invention, there is provided a delivery system for delivering such an miRNA inhibitory complex.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 25, 2022
    Assignees: National University Corporation Chiba University, GeneDesign, Inc., NOF Corporation
    Inventors: Hideo Iba, Takeshi Haraguchi, Hirokazu Nankai, Hideaki Sato
  • Patent number: 11471477
    Abstract: The invention is directed to methods of treating TNBC in a patient by administering to the patient an agent that inhibits the expression or activity of cyclin-dependent kinase 19 (CDK19). In some embodiments, the agent may be a small molecule inhibitor, a polynucleotide (e.g., shRNA. siRNA), or a protein (e.g., an antibody). In some embodiments, the agent does not inhibit the activity or expression of CDK8.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 18, 2022
    Assignees: Chan Zuckerberg Biohub, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Robert W. Hsieh
  • Patent number: 11464836
    Abstract: The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases. In particular, the present invention provides an RNA encoding at least one peptide or protein selected from the group consisting of an extracellular matrix protease, CCAAT/enhancer-binding protein alpha (CEBPA), TNF-related apoptosis-inducing ligand (TRAIL), Hepatocyte Growth Factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), fibroblast growth factor 21 (FGF21), opioid growth factor receptor-like 1 (OGFRL1), Relaxin 1 (RLN1), Relaxin 2 (RLN2) and Relaxin 3 (RLN3), or a fragment or a variant of any of these peptides or proteins. The present invention concerns said RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament, in particular for treatment or prophylaxis of a liver disease.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 11, 2022
    Assignee: CureVac AG
    Inventors: Nigel Horscroft, Marion Pönisch, Christine Weinl-Tenbruck, Frédéric Chevessier-Tünnesen
  • Patent number: 11459567
    Abstract: The present invention generally relates to the field of molecular biology and RNA interference (RNAi). More specifically, the present invention relates to specific siRNA molecules, compositions and uses thereof, as well as methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer. Yet more particularly, the methods of the present invention are methods for inhibiting growth of triple negative breast cancer (TNBC). In a preferred embodiment, the invention provides specific siRNA molecules, comprising a sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, and from any other sequence having a sequence identity greater than 90% between the siRNA and the portion of the target gene. Such siRNA molecules are suitable for the treatment of breast cancer, particularly, TNBC.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: October 4, 2022
    Inventor: Patricia Virginia Elizalde
  • Patent number: 11459352
    Abstract: The present invention is related to a method for the preparation of a modified nucleic acid molecule comprising a nucleic acid moiety and a non-nucleic acid moiety by reacting a first reactant and a second reactant, wherein the first reactant comprises the non-nucleic acid moiety and a carboxyl group, and wherein the second reactant is an amino-modified nucleic acid molecule comprising the nucleic acid moiety and an amino modification comprising an amino group which is attached to the nucleic acid moiety, wherein the method comprises the following steps: a) activating the first reactant, preferably the carboxyl group of the first reactant, by a condensation reagent in a water miscible organic solvent, and b) reacting the activated first reactant, preferably the activated carboxyl group of the first reactant, of step a) and the second reactant, preferably the amino group of the amino modification of the amino-modified nucleic acid molecule which has been dissolved in water or a mixture of a water miscible orga
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 4, 2022
    Assignee: NOXXON Pharma AG
    Inventor: Lucas Bethge
  • Patent number: 11459568
    Abstract: Methods and compositions for treating cancer, e.g., colorectal cancer, using a miR-101-3p inhibitor.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 4, 2022
    Assignee: University of Massachusetts
    Inventors: Louis M. Messina, Guodong Tie
  • Patent number: 11453861
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: September 27, 2022
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Patent number: 11446380
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: September 20, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
  • Patent number: 11447774
    Abstract: Fusion constructs encoding RNase-H-like domain containing compositions are disclosed. Disclosed are also compositions and methods utilizing RNase-H-like domain containing compositions for the treatment of cancer. Also disclosed are the methods of making and using the RNase-H-like domain containing compositions in treating various diseases, conditions, and cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: September 20, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Intima Bioscience, Inc.
    Inventors: Lei S. Qi, Modassir S. Choudhry, Xueqiu Lin, Xiaoshu Xu
  • Patent number: 11446383
    Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 20, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
  • Patent number: 11439657
    Abstract: The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 13, 2022
    Assignee: CancerStem Tech Inc.
    Inventors: Xin Wu, Masaki Mori, Hirofumi Yamamoto
  • Patent number: 11434502
    Abstract: The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 6, 2022
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Qingmin Chen, Holger Patzke, Jinzhao Hou